Christopher Liu
Stock Analyst at Leerink Partners
(2.97)
# 1,548
Out of 5,055 analysts
9
Total ratings
83.33%
Success rate
36.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Upgrades: Outperform | $48 | $41.65 | +15.25% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $16.81 | +18.98% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $1.85 | +386.49% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $5.32 | +87.97% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $6.29 | +186.17% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $32.14 | -15.99% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $96.50 | -56.48% | 1 | Aug 8, 2023 |
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $41.65
Upside: +15.25%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $16.81
Upside: +18.98%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $1.85
Upside: +386.49%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $5.32
Upside: +87.97%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $6.29
Upside: +186.17%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $32.14
Upside: -15.99%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $96.50
Upside: -56.48%